Dr. Judy L. Felgenhauer
Claim this profileProvidence Sacred Heart Medical Center and Children's Hospital
Expert in Tumors
Expert in Brain Tumor
67 reported clinical trials
141 drugs studied
About Judy L. Felgenhauer
Education:
- Obtained MD from the University of Washington School of Medicine in 1987.
- Completed Residency in Pediatrics at the University of Washington Affiliated Hospitals in 1990.
- Concluded Fellowship in Pediatric Cardiology at the University of Washington in 1993.
Experience:
- Affiliated with Providence Sacred Heart Medical Center and Children's Hospital as a pediatric cardiologist.
- Specializes in pediatric cardiology and pediatrics.
Area of expertise
1Tumors
Global LeaderStage I
Stage IV
Stage II
2Brain Tumor
Global LeaderStage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Judy L. Felgenhauer is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
More about Judy L. Felgenhauer
Clinical Trial Related7 years of experience running clinical trials · Led 67 trials as a Principal Investigator · 30 Active Clinical TrialsTreatments Judy L. Felgenhauer has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Vincristine Sulfate
- Nivolumab
Breakdown of trials Judy L. Felgenhauer has run
Tumors
Brain Tumor
Cancer
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Judy L. Felgenhauer specialize in?
Judy L. Felgenhauer focuses on Tumors and Brain Tumor. In particular, much of their work with Tumors has involved Stage I patients, or patients who are Stage IV.
Is Judy L. Felgenhauer currently recruiting for clinical trials?
Yes, Judy L. Felgenhauer is currently recruiting for 22 clinical trials in Spokane Washington. If you're interested in participating, you should apply.
Are there any treatments that Judy L. Felgenhauer has studied deeply?
Yes, Judy L. Felgenhauer has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Judy L. Felgenhauer?
Apply for one of the trials that Judy L. Felgenhauer is conducting.
What is the office address of Judy L. Felgenhauer?
The office of Judy L. Felgenhauer is located at: Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington 99204 United States. This is the address for their practice at the Providence Sacred Heart Medical Center and Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.